April 15, 2021
Japan’s key reimbursement policy panel on April 14 approved the appraisal results for Alexion Pharmaceuticals’ Ultomiris (ravulizumab) under the cost-effectiveness assessment (CEA) system. With a negative valuation given, the drug is now in line for a downward price adjustment. Under...read more